Company Overview and News
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. We expect this strength to further get reflected in second-quarter 2018 results, scheduled for release on Jul 18.
ABT RMD SYK MCK RSMDF RMD ABT
In a bid to strengthen presence in the healthcare sector, Alphabet’s (GOOGL - Free Report) healthcare division Verily is set to form a joint venture with ResMed (RMD - Free Report) . With the aid of this venture, Alphabet strives to help people with undiagnosed and untreated sleep apnea. Notably, sleep apnea is a widespread sleeping disorder which is potentially dangerous. However, most of the cases remain undiagnosed as there is an acute lack of awareness regarding the disease.
RMD FIT GOOGL AAPL RMD
Abbott (ABT - Free Report) is slated to report second-quarter 2018 results before the market opens on Jul 18. Last reported quarter, the company’s earnings per share exceeded the Zacks Consensus Estimate by 1.7%. Moreover, Abbott delivered positive surprises in the trailing four quarters, the average beat being 1.99%.
RMD SYK MCK RSMDF RMD
Brightree, the wholly owned subsidiary of ResMed Inc. (RMD - Free Report) , recently entered into a strategic partnership with athenahealth (ATHN - Free Report) , a leading provider of network-enabled services for hospital and ambulatory clients.
HD RMD SYK RSMDF RMD ABMD ATHN
ResMed Inc. (RMD - Free Report) recently announced positive results from a company-sponsored research, supporting the efficiency of bilevel devices. The results were presented at SLEEP, an annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
RMD RSMDF AMED RMD ISRG ILMN
Last year, InvestorPlace contributor Dan Burrows highlighted the 10 best-performing S&P 500 stocks of the past decade. The most important lesson one finds studying these high-flying stocks is that patience wins out over all other attributes of a successful investor.
BUFF FMAGX UL ULTA RSMDF THI BRK.A SHW RMD VAL AMZN PPG KHC AAPL RMD CBRL FIVE DIS
On May 30, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) , a Zacks Rank #3 (Hold) stock. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Its recent strategic collaborations are also expected to widen its product portfolio.
RMD LOXO RSMDF AMED RMD ISRG ILMN
ResMed, Inc. (RMD - Free Report) recently announced a definitive agreement to buy HEALTHCAREfirst— a privately-held provider of software solutions and services to home health and hospice agencies. After meeting certain customary closing conditions and receiving regulatory approvals, the deal is expected to be finalized before the end of first-quarter fiscal 2019 (per ResMed’s calendar).
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ AMED ISRG ILMN WFC.PRT RMD WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN RMD WFC.PRY WFC.PRX WFC.PRW WFC.PRV
ResMed Inc. (RMD - Free Report) has been gaining investor confidence on consistently positive results. The stock has soared 47.3% over a year compared with the S&P 500’s 12.5% rise and its industry's 15% increase.
RMD RSMDF AMED RMD ISRG ILMN
ResMed Inc. (RMD - Free Report) recently demonstrated a favorable outcome from two clinical analyses in the field of chronic obstructive pulmonary disease (COPD). These studies were conducted for the United Kingdom and the United States, highlighting the cost effectiveness of combining home oxygen therapy with home non-invasive ventilation (NIV) therapy for persistent hypercapnia patients, who suffer exacerbation of COPD.
COO RMD RSMDF RMD ISRG ILMN
Inogen blew away sell-side expectations in the first quarter and despite conservative guidance, investments in DTC sales and B2B relationships could deliver more upside.
RMD INGN RMD
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ASX:RMD / RESMED INC on message board site Silicon Investor.